Novartis iptacopan meets primary endpoint in new rare kidney disease trial
PharmiWeb,
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant…
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant…
Phase III APPLAUSE-IgAN study met its pre-specified interim analysis primary endpoint, demonstrating superiority of iptacopan…
GlobeNewswire 2023-10-02 Ad hoc announcement pursuant to Art. 53 LR Basel, October 2, 2023 — Novartis today announced positive…
Ad hoc announcement pursuant to Art. 53 LR Phase III APPLAUSE-IgAN study met its pre-specified interim analysis primary endpoint…
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library https://www.novartis.com/news/media-lib…
Phase III APPLAUSE-IgAN study met its pre-specified interim analysis primary endpoint, demonstrating superiority of iptacopan…
Ad hoc announcement pursuant to Art. 53 LR Phase III APPLAUSE-IgAN study met its pre-specified interim analysis primary endpoint…
Ad hoc announcement pursuant to Art. 53 LR Phase III APPLAUSE-IgAN study met its pre-specified interim analysis primary endpoint…
Ad hoc announcement pursuant to Art. 53 LR Basel, October 2, 2023 — Novartis today announced positive top-line results from the…
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library https://www.novartis.com/news/media-lib…
Ad hoc announcement pursuant to Art. 53 LR Phase III APPLAUSE-IgAN study met its pre-specified interim analysis primary endpoint…